治疗前情绪困扰与晚期黑色素瘤TIL治疗疗效的关联
该研究对III期TIL试验(NCT02278887)进行事后分析,采用事件影响量表与EORTC QLQ-C15-PAL情绪功能子量表复合评分,按中位数将患者分为高情绪困扰组(n=32)和正常组(n=40)。结果显示高情绪困扰与客观缓解率降低(37% vs 69%)及1年、2年无进展生存率下降相关。
要点
- 治疗前高情绪困扰与TIL治疗后客观缓解率降低相关(37% vs 69%)。
- 高情绪困扰组1年及2年无进展生存率均低于正常组(31% vs 58%;16% vs 35%)。
- 敏感性分析按三分位分组呈现相似趋势,但未达统计学显著。
核心结论
- 治疗前高情绪困扰与晚期黑色素瘤患者TIL治疗疗效降低相关。
研究设计与样本
- III期TIL试验(NCT02278887)的事后分析,共纳入按中位数分组的72例患者(高情绪困扰组n=32,正常组n=40)。
- 情绪困扰采用事件影响量表与EORTC QLQ-C15-PAL情绪功能子量表的复合评分评估。
- 敏感性分析按复合评分三分位分组比较最低三分位(n=26)与最高三分位(n=25)患者的结局。
主要发现
- 高情绪困扰组客观缓解率为37%,正常组为69%(调整OR=0.28,95%CI 0.19-0.75,P=0.013)。
- 高情绪困扰组1年无进展生存率为31%,正常组为58%;2年分别为16%与35%(调整HR=1.84,95%CI 1.03-3.26,P=0.038)。
- 三分位分组敏感性分析显示相似趋势(OR=0.35,95%CI 0.11-1.08,P=0.072)。
临床怎么用
- 对拟接受TIL治疗的晚期黑色素瘤患者,可考虑评估治疗前情绪困扰以识别可能疗效不佳者。
- 情绪困扰评估可作为TIL治疗预后分层及支持干预的参考因素。
局限性
- 本研究为III期试验的事后分析,样本量有限(共72例),结果需前瞻性验证。
- 情绪困扰分组采用中位数分割法,敏感性分析结果未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has demonstrated benefit for patients with advanced melanoma refractory to first-line immune checkpoint inhibitors (ICIs). However, predictive biomarkers for TIL therapy response are limited. Preclinical studies suggest that emotional distress (ED) may impair antitumor immune responses. We conducted a post-hoc analysis of the phase III TIL trial (NCT02278887) to evaluate the association between pretreatment ED and TIL therapy outcomes. METHODS: ED was evaluated using a composite score derived from the Impact of Event Scale and the emotional functioning subscale of the EORTC QLQ-C15-PAL. Patients were stratified into elevated ED (n = 32) or normal ED (n = 40) groups using a median split approach. To evaluate whether the obtained results were dependent on the ED classification method, a sensitivity analysis was conducted to compare TIL therapy outcomes between patients with composite ED scores in the lowest tertile (normal ED, n = 26) and highest tertile (elevated ED, n = 25). RESULTS: Elevated ED was associated with a reduced objective response rate (37 % vs. 69 %; adjusted odds ratio, 0.28; 95 % confidence interval [CI], 0.19-0.75; P = 0.013) and decreased progression-free survival rates at 1-year (31 % vs. 58 %) and 2-years (16 % vs. 35 %; adjusted hazard ratio, 1.84; 95 % CI, 1.03-3.26; P = 0.038). Sensitivity analysis using the tertile grouping method showed a similar trend (odds ratio, 0.35; 95 % CI, 0.11-1.08, P = 0.072). CONCLUSION: Our findings suggest that elevated ED before TIL therapy is associated with reduced therapeutic outcomes, underscoring the need for further investigation into the stress-immune-cancer axis.
引用
- Egeler MD, Klobuch S, Tak WS, et al. The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma. Eur J Cancer. 2025. PMID: 40674829. doi:10.1016/j.ejca.2025.115640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。